Nishit Choksi, MD
Cardiovascular Disease · Dearborn, MINPI 1992764641
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Cardiovascular Systems Inc. at 27.1% of the total. Reporting peaked in 2022 at $9,223 and has fallen 58.1% since, to $3,862 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 822 payments — averaging $49.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$11K
- Edwards Lifesciences$6K
- Abbott$4K
- Endologix LLC$3K
- Shockwave Medical, Inc$2K
- Novartis$1K
- plus $13K from 54 others
Across 46 payments — averaging $1901.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$63K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
- Novartis$7K
- Vifor (international) Ltd.$5K
What the payments were for
- Consulting fees$3,7509%
- Speaking & faculty fees$10,99527%
- Travel & lodging$4,00510%
- Food & beverage$21,89053%
- Education$3291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Diamondback Coronary$8,370
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,176
- Peripheral Orbital Atherectomy System$1,884
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,875
- Mitra Clip system$1,546
- Venclose Maven Catheter$739
- FFRct$528
- OPTIMIZER$487
- FLOWTRIEVER CATHETER, S$473
- CoreValve Evolut$385
- PASCAL$311
- Navicross$265
- XARELTO$231
- AMPLATZER Occluders$162
- Xience Sierra Coronary Stent$161
- WATCHMAN FLX$149
- GlideWire$143
- CLOTTRIEVER BOLD CATHETER$140
- ESPRIT$130
- Optis Coronary Imaging System$130
How this compares
$40,969 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 522 | $628,308 |
| EntrestoSacubitril/Valsartan | 385 | $472,586 |
| XareltoRivaroxaban | 107 | $143,352 |
| JardianceEmpagliflozin | 94 | $113,739 |
| Repatha SureclickEvolocumab | 95 | $88,488 |
| VerquvoVericiguat | 80 | $85,308 |
| FarxigaDapagliflozin Propanediol | 66 | $68,542 |
| BrilintaTicagrelor | 77 | $63,498 |
| Praluent PenAlirocumab | 23 | $21,781 |
| Repatha SyringeEvolocumab | 28 | $20,296 |
| ClopidogrelClopidogrel Bisulfate | 1,043 | $19,553 |
| Metoprolol Succinate | 884 | $15,696 |
| Ranolazine ErRanolazine | 134 | $14,343 |
| Atorvastatin Calcium | 986 | $12,415 |
| Midodrine Hcl | 71 | $6,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $302 | $628,308522 claims |
| NovartisEntresto | $1,320 | $472,586385 claims |
| Johnson & JohnsonXarelto | $1,066 | $143,352107 claims |
| AstraZenecaFarxiga, Brilinta | $828 | $132,040143 claims |
| Boehringer IngelheimJardiance | $386 | $113,73994 claims |
| MerckVerquvo | $811 | $85,30880 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$172K
- Sohail HassanDearborn$121K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.